Capricor Therapeutics Inc... (CAPR)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 14.25 |
Market Cap | 658.86M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.02 |
PE Ratio (ttm) | -14.21 |
Forward PE | n/a |
Analyst | Buy |
Ask | 15.1 |
Volume | 490,100 |
Avg. Volume (20D) | 1,269,403 |
Open | 14.64 |
Previous Close | 14.90 |
Day's Range | 14.21 - 14.86 |
52-Week Range | 3.52 - 23.40 |
Beta | undefined |
About CAPR
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Ph...
Analyst Forecast
According to 7 analyst ratings, the average rating for CAPR stock is "Buy." The 12-month stock price forecast is $32.5, which is an increase of 124.29% from the latest price.
Next Earnings Release
Analysts project revenue of $9.87M, reflecting a -18.35% YoY shrinking and earnings per share of -0.09, making a 350.00% increase YoY.
Why Price Moved
News
1 month ago · seekingalpha.com
Deramiocel's Promise Brightens Capricor's Outlook, With Strings AttachedCapricor Therapeutics is advancing deramiocel, an allogeneic cell therapy for DMD-related cardiomyopathy, with a rolling BLA submission and potential FDA approval by 2025. Deramiocel showed significan...
2 months ago · seekingalpha.com
Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call TranscriptCapricor Therapeutics, Inc. (NASDAQ:CAPR ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marbán - Chief Executive Off...